- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- January 2024
- 200 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- February 2024
- 150 Pages
Global
From €4095EUR$4,250USD£3,523GBP
- Report
- January 2022
- 419 Pages
Global
From €9154EUR$9,500USD£7,874GBP
- Report
- November 2021
- 101 Pages
Global
From €4336EUR$4,500USD£3,730GBP
- Report
- July 2018
- 17 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Report
- July 2018
- 30 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Report
- July 2018
- 41 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Drug Pipelines
- February 2018
- 39 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Drug Pipelines
- February 2018
- 16 Pages
Global
From €9636EUR$10,000USD£8,289GBP
- Report
- April 2023
- 156 Pages
Global
€4818EUR$5,000USD£4,144GBP
- Report
- April 2023
- 114 Pages
Global
€3373EUR$3,500USD£2,901GBP
- Report
- March 2023
- 147 Pages
Global
From €5781EUR$5,999USD£4,972GBP
Fluticasone Furoate is a corticosteroid used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is used to reduce inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath. Fluticasone Furoate is available in both inhaler and nasal spray forms, and is often used in combination with other medications to provide the best results.
Fluticasone Furoate is a widely used medication in the respiratory drug market, and is often prescribed as a first-line treatment for asthma and COPD. It is generally well-tolerated and has few side effects, making it a popular choice for many patients.
Some companies that produce Fluticasone Furoate include GlaxoSmithKline, Merck, and Mylan. Other companies that produce generic versions of the drug include Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more